# Practical insights for the clinical implementation of the EULAR recommendations for patients with systemic lupus erythematosus

## TL;DR

This paper offers practical advice for doctors to implement EULAR guidelines for treating systemic lupus erythematosus, focusing on diagnosis, treatment, and monitoring.

## Contribution

Provides expert-driven, actionable insights to overcome real-world barriers in applying EULAR recommendations for SLE management.

## Key findings

- Experts identified 13 core advice points for implementing EULAR recommendations in SLE care.
- Advice includes scenarios for early use of biologics and immunosuppressants, and strategies for glucocorticoid tapering.
- Monitoring through validated tools and setting standardized treatment targets are emphasized to prevent organ damage.

## Abstract

The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for practitioners on diagnosis, monitoring and treatment. However, practical barriers, such as time constraints, may pose challenges to practitioners when implementing these recommendations in real-world settings. We provide practical, expert-driven advice on how practitioners may effectively and efficiently implement the EULAR recommendations in routine clinical practice.

Eight international SLE experts convened and contributed opinions and advice for practitioners via an online survey containing 17 open-ended questions on implementation of the EULAR recommendations for early diagnosis, treatment targets and the use of glucocorticoids (GCs), immunosuppressants and biologics. Survey results were compiled and analysed to reach consensus on key advice points for each topic.

Expert advice covered four key topics—setting standardised targets to help modify disease course and prevent organ damage; taking action to achieve these targets; monitoring of target achievement through validated clinical tools and frameworks; and optimising the therapeutic strategy to prevent flares and GC-associated toxicities. A total of 13 core expert-driven advice points were developed across these topics, including scenarios for consideration of earlier biological and/or conventional immunosuppressive use, specific risk factors for poorer prognosis to inform treatment decisions and suggestions on GC tapering.

These expert insights could facilitate implementation of the EULAR recommendations for the management of SLE in clinical practice, thereby helping patients achieve treatment targets and prevent and/or delay organ damage progression.